Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary

Yehuda Handelsman, Paul S. Jellinger, Chris K. Guerin, Zachary T. Bloomgarden, Eliot A. Brinton, Matthew J. Budoff, Michael H. Davidson, Daniel Einhorn, Sergio Fazio, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Ronald M. Krauss, Jeffrey I. Mechanick, Paul D. Rosenblit, Donald A. Smith, Kathleen L. Wyne

Research output: Contribution to journalArticlepeer-review

106 Scopus citations

Abstract

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient s risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/ dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides =500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with =2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.

Original languageEnglish
Pages (from-to)1196-1224
Number of pages29
JournalEndocrine Practice
Volume26
Issue number10
DOIs
StatePublished - Oct 2020

Fingerprint

Dive into the research topics of 'Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary'. Together they form a unique fingerprint.

Cite this